KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aurinia Pharmaceuticals (AUPH) Receivables - Net: 2018-2025

Historic Receivables - Net for Aurinia Pharmaceuticals (AUPH) over the last 7 years, with Sep 2025 value amounting to $30.7 million.

  • Aurinia Pharmaceuticals' Receivables - Net fell 15.81% to $30.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $30.7 million, marking a year-over-year decrease of 15.81%. This contributed to the annual value of $36.5 million for FY2024, which is 51.70% up from last year.
  • Aurinia Pharmaceuticals' Receivables - Net amounted to $30.7 million in Q3 2025, which was down 23.35% from $40.1 million recorded in Q2 2025.
  • Aurinia Pharmaceuticals' 5-year Receivables - Net high stood at $41.8 million for Q3 2022, and its period low was $1.2 million during Q1 2021.
  • For the 3-year period, Aurinia Pharmaceuticals' Receivables - Net averaged around $30.8 million, with its median value being $30.7 million (2025).
  • Its Receivables - Net has fluctuated over the past 5 years, first surged by 1,600.08% in 2022, then declined by 15.81% in 2025.
  • Quarterly analysis of 5 years shows Aurinia Pharmaceuticals' Receivables - Net stood at $15.4 million in 2021, then fell by 12.42% to $13.5 million in 2022, then skyrocketed by 78.44% to $24.1 million in 2023, then soared by 51.70% to $36.5 million in 2024, then dropped by 15.81% to $30.7 million in 2025.
  • Its last three reported values are $30.7 million in Q3 2025, $40.1 million for Q2 2025, and $40.4 million during Q1 2025.